Pharmaceutical - Daiichi Sankyo, USA

Filter

Current filters:

Daiichi SankyoUSA

Popular Filters

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

10-07-2014

USA-based Portola Pharmaceuticals has entered into a second clinical collaboration agreement with Japanese…

andexanet alfaCardio-vascularDaiichi SankyoedoxabanJapanLicensingPharmaceuticalPortola PharmaceuticalsResearchSavaysaUSA

FDA review of CV risks for diabetics taking olmesartan not conclusive

FDA review of CV risks for diabetics taking olmesartan not conclusive

25-06-2014

The US Food and Drug Administration has completed its safety review and has found no clear evidence of…

BenicarCardio-vascularDaiichi SankyoDiabetesolmesartanPharmaceuticalRegulationUSA

Daiichi Sankyo names Ken Keller as President, US Commercial

Daiichi Sankyo names Ken Keller as President, US Commercial

23-04-2014

Japanese drugmaker Daiichi Sankyo has announced that Ken Keller will join the company as President of…

AmgenBoardroomBusiness FinanceDaiichi SankyoHealth Medical PharmaJapanKen KellerPharmaceuticalPharmaceutical experienceUSA

Daiichi Sankyo files Savaysa for US approval; collaborates with Virtici and Celdara Medical

Daiichi Sankyo files Savaysa for US approval; collaborates with Virtici and Celdara Medical

10-01-2014

Japanese drug major Daiichi Sankyo has filed a New Drug Application for its investigational, oral, once-daily…

Cardio-vascularCeldara MedicalDaiichi SankyoedoxabanNorth AmericaPharmaceuticalRegulationResearchSavaysaUSAVirtici

Company Spotlight

ImmunoGen

ImmunoGen

Back to top